<p>製造商人壽保險公司在最近向證券交易委員會提交的文件中表示，在第四季度將其在 Protagonist Therapeutics, Inc.（NASDAQ:PTGX - 免費報告）的持股增加了 7.4%。該公司在此期間購買了 8,576 股後，持有 124,341 股該公司的股票。製造商人壽保險公司在最近的報告期末持有 Protagonist Therapeutics 約 0.21% 的股份，價值 4,800,000 美元。</p>
<ul>
<li>這隻小型生物科技股票是否還有更大的收益？</li>
</ul>
<p>其他一些機構投資者和對沖基金最近也對其在 PTGX 的持倉進行了調整。威靈頓管理集團在第四季度將其在 Protagonist Therapeutics 的持股增加了 3,025.4%。威靈頓管理集團現在擁有 940,077 股該公司的股票，價值 36,287,000 美元，此前在上個季度購買了 909,998 股。美國世紀公司在第四季度將其在 Protagonist Therapeutics 的持股增加了 61.5%。美國世紀公司現在擁有 928,286 股該公司的股票，價值 35,832,000 美元，此前在上個季度購買了 353,511 股。首都金融集團在第三季度將其在 Protagonist Therapeutics 的持倉增加了 3,099.4%。首都金融集團現在擁有 320,832 股該公司的股票，價值 14,437,000 美元，此前在上個季度購買了 310,804 股。雷蒙德·詹姆斯金融公司在第四季度購買了 Protagonist Therapeutics 的新股份，價值 11,708,000 美元。最後，Pictet 資產管理控股公司在第四季度將其在 Protagonist Therapeutics 的持倉增加了 3,962.9%。Pictet 資產管理控股公司現在擁有 296,511 股該公司的股票，價值 11,445,000 美元，此前在上個季度購買了 289,213 股。對沖基金和其他機構投資者持有該公司 98.63% 的股票。</p>
<h2>Protagonist Therapeutics 的內部買賣</h2>
<p>在其他消息中，首席執行官 Dinesh V. Ph D. Patel 在 2 月 19 日（星期三）出售了 5,359 股該公司的股票。股票以平均價格 38.18 美元出售，總價值為 204,606.62 美元。出售完成後，首席執行官現在持有 540,260 股該公司的股票，價值約為 20,627,126.80 美元。這代表其持股減少了 0.98%。該出售在向證券交易委員會提交的文件中披露，可以通過此鏈接訪問。此外，內部人士 Arturo Md Molina 在 3 月 13 日（星期四）出售了 30,514 股 Protagonist Therapeutics 的股票。股票以平均價格 55.74 美元出售，總交易額為 1,700,850.36 美元。交易後，該內部人士現在直接持有 83,892 股該公司的股票，價值約為 4,676,140.08 美元。這筆交易使其持股減少了 26.67%。該出售的披露信息可以在這裏找到。內部人士在過去九十天內共出售了 66,532 股公司股票，價值 3,665,786 美元。公司內部人士持有該公司 5.40% 的股票。</p>
<h2>分析師設定新的價格目標</h2>
<p>一些券商最近對 PTGX 發表了評論。Wedbush 在 3 月 28 日（星期五）的報告中重申了 “跑贏大盤” 的評級，並對 Protagonist Therapeutics 的股票設定了 70.00 美元的價格目標。高盛集團在 2 月 24 日（星期一）的報告中將 Protagonist Therapeutics 的目標價格從 43.00 美元下調至 38.00 美元，並對該公司設定了 “中性” 評級。摩根大通在 3 月 4 日（星期二）的報告中將 Protagonist Therapeutics 的目標價格從 53.00 美元提高至 57.00 美元，並給予該公司 “增持” 評級。JMP 證券在 2 月 7 日（星期五）的研究報告中重申了 “市場跑贏大盤” 的評級，並對 Protagonist Therapeutics 的股票設定了 58.00 美元的價格目標。最後，HC Wainwright 在 4 月 10 日（星期四）的研究報告中重新發布了 “買入” 評級，並對 Protagonist Therapeutics 的股票設定了 80.00 美元的目標價格。兩位股票研究分析師對該股票給予了持有評級，七位給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，共識目標價格為 65.44 美元。</p>
<p><strong>獲取我們最新的 PTGX 股票分析</strong></p>
<h2>Protagonist Therapeutics 上漲 2.1%</h2>
<p>NASDAQ PTGX 在星期五開盤價為 43.98 美元。該股票的市值為 27.2 億美元，市盈率為 16.53，貝塔值為 2.65。Protagonist Therapeutics, Inc.的 12 個月低點為 26.79 美元，12 個月高點為 60.60 美元。該公司的 50 日移動平均價格為 46.87 美元，200 日移動平均價格為 42.75 美元。</p>
<p>Protagonist Therapeutics（NASDAQ:PTGX - 獲取免費報告）最近在 5 月 6 日（星期二）發佈了其財報。該公司報告本季度每股收益為（0.19）美元，超過分析師的共識預期（0.50）美元，超出 0.31 美元。該季度的營業收入為 2832 萬美元，而共識預期為 3044 萬美元。Protagonist Therapeutics 的淨利潤率為 52.76%，股本回報率為 34.68%。作為一個整體，賣方分析師預測 Protagonist Therapeutics, Inc.在當前年度將發佈 2.43 美元的每股收益。</p>
<h2>Protagonist Therapeutics 公司簡介</h2>
<p>（免費報告）</p>
<p>Protagonist Therapeutics, Inc.是一家生物製藥公司，開發用於血液學和血液疾病以及炎症和免疫調節疾病的基於肽的藥物。該公司正在開發 Rusfertide（PTG-300），這是一種可注射的肝素模仿物，已完成針對真性紅細胞增多症和其他血液疾病的二期臨牀試驗；以及 JNJ-2113，這是一種口服給藥的研究藥物，旨在阻斷生物通路，已完成針對中度至重度斑塊型銀屑病的二期 b 臨牀試驗；以及 PN-943，這是一種口服給藥、腸道限制的α4β7 特異性整合素拮抗劑，已在中度至重度潰瘍性結腸炎患者中完成二期臨牀試驗。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 Protagonist Therapeutics 更好</li>
<li>技術指標如何幫助你找到被超賣的股票</li>
<li>IBM 的人工智能攻勢：評估 IBM 重獲增長的路徑</li>
<li>每月分紅股票的利與弊</li>
<li>羅克韋爾自動化：美國生產回流的順風</li>
<li>投資者最重要的沃倫·巴菲特股票：他自己的股票</li>
<li>能源轉移是被低估還是價值陷阱？</li>
</ul>
<p><strong>想看看其他對 PTGX 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com，獲取 Protagonist Therapeutics, Inc.（NASDAQ:PTGX - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRHWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRHWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Protagonist Therapeutics 嗎？</h2>
<p>在你考慮 Protagonist Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前...而 Protagonist Therapeutics 並不在名單上。</p>
<p>雖然 Protagonist Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Protagonist治療

<p>製造商人壽保險公司將其在 Protagonist Therapeutics, Inc.（納斯達克代碼：PTGX）的股份增加了 7.4%，額外購買了 8,576 股，總持股量達到 124,341 股，價值約為 480 萬美元。其他機構投資者也顯著增加了他們的持股。內部交易方面，首席執行官 Dinesh V. Ph D. Patel 出售了 5,359 股。分析師對 PTGX 的評級不一，價格目標範圍從 38 美元到 80 美元，反映出 “適度買入” 的共識評級。該股票目前交易價格為 43.98 美元，市值為 27.2 億美元</p>

<p>The Manufacturers Life Insurance Company lifted its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 7.4% during the 4th quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The firm owned 124,341 shares of the company's stock after purchasing an additional 8,576 shares during the period. The Manufacturers Life Insurance Company owned about 0.21% of Protagonist Therapeutics worth $4,800,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>製造商人壽保險公司在最近向證券交易委員會提交的文件中表示，在第四季度將其在 Protagonist Therapeutics, Inc.（NASDAQ:PTGX - 免費報告）的持股增加了 7.4%。該公司在此期間購買了 8,576 股後，持有 124,341 股該公司的股票。製造商人壽保險公司在最近的報告期末持有 Protagonist Therapeutics 約 0.21% 的股份，價值 4,800,000 美元。</p>
</div><ul>
<li>Are (More) Big Gains Ahead for This Small Cap Biotech Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>這隻小型生物科技股票是否還有更大的收益？</li>
</ul>
</div><p>A number of other institutional investors and hedge funds also recently made changes to their positions in PTGX. Wellington Management Group LLP lifted its holdings in shares of Protagonist Therapeutics by 3,025.4% in the fourth quarter. Wellington Management Group LLP now owns 940,077 shares of the company's stock worth $36,287,000 after buying an additional 909,998 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Protagonist Therapeutics by 61.5% in the fourth quarter. American Century Companies Inc. now owns 928,286 shares of the company's stock valued at $35,832,000 after purchasing an additional 353,511 shares in the last quarter. Principal Financial Group Inc. increased its position in Protagonist Therapeutics by 3,099.4% in the third quarter. Principal Financial Group Inc. now owns 320,832 shares of the company's stock worth $14,437,000 after purchasing an additional 310,804 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Protagonist Therapeutics during the fourth quarter valued at $11,708,000. Finally, Pictet Asset Management Holding SA lifted its position in Protagonist Therapeutics by 3,962.9% during the fourth quarter. Pictet Asset Management Holding SA now owns 296,511 shares of the company's stock valued at $11,445,000 after purchasing an additional 289,213 shares during the last quarter. Hedge funds and other institutional investors own 98.63% of the company's stock.</p>
<div class="lb-trans"><p>其他一些機構投資者和對沖基金最近也對其在 PTGX 的持倉進行了調整。威靈頓管理集團在第四季度將其在 Protagonist Therapeutics 的持股增加了 3,025.4%。威靈頓管理集團現在擁有 940,077 股該公司的股票，價值 36,287,000 美元，此前在上個季度購買了 909,998 股。美國世紀公司在第四季度將其在 Protagonist Therapeutics 的持股增加了 61.5%。美國世紀公司現在擁有 928,286 股該公司的股票，價值 35,832,000 美元，此前在上個季度購買了 353,511 股。首都金融集團在第三季度將其在 Protagonist Therapeutics 的持倉增加了 3,099.4%。首都金融集團現在擁有 320,832 股該公司的股票，價值 14,437,000 美元，此前在上個季度購買了 310,804 股。雷蒙德·詹姆斯金融公司在第四季度購買了 Protagonist Therapeutics 的新股份，價值 11,708,000 美元。最後，Pictet 資產管理控股公司在第四季度將其在 Protagonist Therapeutics 的持倉增加了 3,962.9%。Pictet 資產管理控股公司現在擁有 296,511 股該公司的股票，價值 11,445,000 美元，此前在上個季度購買了 289,213 股。對沖基金和其他機構投資者持有該公司 98.63% 的股票。</p>
</div><h2>Insider Buying and Selling at Protagonist Therapeutics</h2>
<div class="lb-trans"><h2>Protagonist Therapeutics 的內部買賣</h2>
</div><p>In other news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the company's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $38.18, for a total value of $204,606.62. Following the completion of the sale, the chief executive officer now owns 540,260 shares of the company's stock, valued at approximately $20,627,126.80. This represents a 0.98 % decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, insider Arturo Md Molina sold 30,514 shares of Protagonist Therapeutics stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the transaction, the insider now directly owns 83,892 shares in the company, valued at approximately $4,676,140.08. The trade was a 26.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 66,532 shares of company stock valued at $3,665,786 in the last ninety days. Corporate insiders own 5.40% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席執行官 Dinesh V. Ph D. Patel 在 2 月 19 日（星期三）出售了 5,359 股該公司的股票。股票以平均價格 38.18 美元出售，總價值為 204,606.62 美元。出售完成後，首席執行官現在持有 540,260 股該公司的股票，價值約為 20,627,126.80 美元。這代表其持股減少了 0.98%。該出售在向證券交易委員會提交的文件中披露，可以通過此鏈接訪問。此外，內部人士 Arturo Md Molina 在 3 月 13 日（星期四）出售了 30,514 股 Protagonist Therapeutics 的股票。股票以平均價格 55.74 美元出售，總交易額為 1,700,850.36 美元。交易後，該內部人士現在直接持有 83,892 股該公司的股票，價值約為 4,676,140.08 美元。這筆交易使其持股減少了 26.67%。該出售的披露信息可以在這裏找到。內部人士在過去九十天內共出售了 66,532 股公司股票，價值 3,665,786 美元。公司內部人士持有該公司 5.40% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>A number of brokerages recently commented on PTGX. Wedbush reaffirmed an &#34;outperform&#34; rating and issued a $70.00 price target on shares of Protagonist Therapeutics in a report on Friday, March 28th. The Goldman Sachs Group dropped their target price on Protagonist Therapeutics from $43.00 to $38.00 and set a &#34;neutral&#34; rating for the company in a report on Monday, February 24th. JPMorgan Chase &amp; Co. increased their price target on Protagonist Therapeutics from $53.00 to $57.00 and gave the company an &#34;overweight&#34; rating in a report on Tuesday, March 4th. JMP Securities reaffirmed a &#34;market outperform&#34; rating and set a $58.00 price objective on shares of Protagonist Therapeutics in a research note on Friday, February 7th. Finally, HC Wainwright reissued a &#34;buy&#34; rating and issued a $80.00 target price on shares of Protagonist Therapeutics in a research note on Thursday, April 10th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $65.44.</p>
<div class="lb-trans"><p>一些券商最近對 PTGX 發表了評論。Wedbush 在 3 月 28 日（星期五）的報告中重申了 “跑贏大盤” 的評級，並對 Protagonist Therapeutics 的股票設定了 70.00 美元的價格目標。高盛集團在 2 月 24 日（星期一）的報告中將 Protagonist Therapeutics 的目標價格從 43.00 美元下調至 38.00 美元，並對該公司設定了 “中性” 評級。摩根大通在 3 月 4 日（星期二）的報告中將 Protagonist Therapeutics 的目標價格從 53.00 美元提高至 57.00 美元，並給予該公司 “增持” 評級。JMP 證券在 2 月 7 日（星期五）的研究報告中重申了 “市場跑贏大盤” 的評級，並對 Protagonist Therapeutics 的股票設定了 58.00 美元的價格目標。最後，HC Wainwright 在 4 月 10 日（星期四）的研究報告中重新發布了 “買入” 評級，並對 Protagonist Therapeutics 的股票設定了 80.00 美元的目標價格。兩位股票研究分析師對該股票給予了持有評級，七位給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，共識目標價格為 65.44 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on PTGX</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 PTGX 股票分析</strong></p>
</div><h2>Protagonist Therapeutics Trading Up 2.1 %</h2>
<div class="lb-trans"><h2>Protagonist Therapeutics 上漲 2.1%</h2>
</div><p>NASDAQ PTGX opened at $43.98 on Friday. The stock has a market cap of $2.72 billion, a PE ratio of 16.53 and a beta of 2.65. Protagonist Therapeutics, Inc. has a 12 month low of $26.79 and a 12 month high of $60.60. The company's 50-day moving average price is $46.87 and its 200-day moving average price is $42.75.</p>
<div class="lb-trans"><p>NASDAQ PTGX 在星期五開盤價為 43.98 美元。該股票的市值為 27.2 億美元，市盈率為 16.53，貝塔值為 2.65。Protagonist Therapeutics, Inc.的 12 個月低點為 26.79 美元，12 個月高點為 60.60 美元。該公司的 50 日移動平均價格為 46.87 美元，200 日移動平均價格為 42.75 美元。</p>
</div><p>Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.31. The business had revenue of $28.32 million for the quarter, compared to the consensus estimate of $30.44 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. As a group, sell-side analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.</p>
<div class="lb-trans"><p>Protagonist Therapeutics（NASDAQ:PTGX - 獲取免費報告）最近在 5 月 6 日（星期二）發佈了其財報。該公司報告本季度每股收益為（0.19）美元，超過分析師的共識預期（0.50）美元，超出 0.31 美元。該季度的營業收入為 2832 萬美元，而共識預期為 3044 萬美元。Protagonist Therapeutics 的淨利潤率為 52.76%，股本回報率為 34.68%。作為一個整體，賣方分析師預測 Protagonist Therapeutics, Inc.在當前年度將發佈 2.43 美元的每股收益。</p>
</div><h2>Protagonist Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Protagonist Therapeutics 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.</p>
<div class="lb-trans"><p>Protagonist Therapeutics, Inc.是一家生物製藥公司，開發用於血液學和血液疾病以及炎症和免疫調節疾病的基於肽的藥物。該公司正在開發 Rusfertide（PTG-300），這是一種可注射的肝素模仿物，已完成針對真性紅細胞增多症和其他血液疾病的二期臨牀試驗；以及 JNJ-2113，這是一種口服給藥的研究藥物，旨在阻斷生物通路，已完成針對中度至重度斑塊型銀屑病的二期 b 臨牀試驗；以及 PN-943，這是一種口服給藥、腸道限制的α4β7 特異性整合素拮抗劑，已在中度至重度潰瘍性結腸炎患者中完成二期臨牀試驗。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Protagonist Therapeutics</li>
<li>How Technical Indicators Can Help You Find Oversold Stocks</li>
<li>IBM's AI Offensive: Assessing IBM's Path to Renewed Growth</li>
<li>Pros And Cons Of Monthly Dividend Stocks</li>
<li>Rockwell Automation: Tailwinds From Onshoring U.S. Production</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>Is Energy Transfer Undervalued or a Value Trap?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Protagonist Therapeutics 更好</li>
<li>技術指標如何幫助你找到被超賣的股票</li>
<li>IBM 的人工智能攻勢：評估 IBM 重獲增長的路徑</li>
<li>每月分紅股票的利與弊</li>
<li>羅克韋爾自動化：美國生產回流的順風</li>
<li>投資者最重要的沃倫·巴菲特股票：他自己的股票</li>
<li>能源轉移是被低估還是價值陷阱？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PTGX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 PTGX 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com，獲取 Protagonist Therapeutics, Inc.（NASDAQ:PTGX - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRHWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PTGX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Protagonist Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Protagonist Therapeutics 嗎？</h2>
</div><p>Before you consider Protagonist Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Protagonist Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protagonist Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前...而 Protagonist Therapeutics 並不在名單上。</p>
</div><p>While Protagonist Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Protagonist Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

製造商人壽保險公司購入了 8,576 股 Protagonist Therapeutics, Inc.（NASDAQ:PTGX）的股票